DSG3 and pemphigus: Since RTX is approved as a first-line treatment for pemphigus, we assessed whether the number and the isotypes of anti-DSG3 IgG subclasses in sera from patients at the onset of pemphigus might predict the occurrence of relapses under treatment or after treatment withdrawal.